Moderna Inc. said on Oct. 25 the company’s Covid-19 vaccine generated a strong immune response in children aged 6 to 11 years and plans to submit the data to global regulators soon.

The Centers for Disease Control and Prevention gave the go-ahead for the use of Moderna’s and Janssen’s Covid-19 vaccines as booster shots six months and two months, respectively, after their initial series as well as the approval of mixing and matching vaccines. 

Pfizer, Moderna, and AstraZeneca have been running “dress rehearsals” by adapting their current formulations of Covid-19 vaccines to match present known SARS-CoV-2 variants.

The U.S. Food and Drug Administration on Oct. 20 authorized booster doses of the Covid-19 vaccines from Moderna Inc. and Johnson & Johnson, and the regulatory agency said Americans can choose a different shot from their original inoculation as a booster.

The U.S. Food and Drug Administration is planning to allow Americans to get a different booster shot of a Covid-19 vaccine than the one initially taken, the New York Times reported on Oct. 18.

A panel of expert advisers to the U.S. Food and Drug Administration unanimously voted on Oct. 14 to recommend booster shots of Moderna Inc.’s Covid-19 vaccine for Americans aged 65 and older and those at high risk of severe illness or occupational exposure to the virus.

People who got Johnson & Johnson’s Covid-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer/BioNTech or Moderna, a study run by the National Institutes of Health showed on Oct. 13.

Scientists at the U.S. Food and Drug Administration said on Oct. 12 that Moderna Inc. had not met all of the regulatory agency’s criteria to support use of booster doses of the company’s Covid-19 vaccine, possibly because the efficacy of the shot’s first two doses has remained strong.

According to a Wall Street Journal report, the preferred Covid-19 shot globally is the Pfizer-BioNTech vaccine.

The United States had administered 401,819,240 doses of Covid-19 vaccines in the country as of the morning of Oct. 9 and distributed 487,277,035 doses, the U.S. Centers for Disease Control and Prevention said.